In klinischen Studien kam es bei wenigen Patienten (< 0,3%) zu Perforationen, Obstruktionen oder Blutungen (POB).
In clinical studies, few patients (< 0.3%) treated with lumiracoxib developed perforations, obstruction or bleeds (POBs).